To Launch Ducarb Plus in Mexico Within This Year
Boryung Pharmaceutical announced on Feb. 27 that Korean and Mexican cardiovascular internal medicine experts shared the clinical effects and prescription cases of the Kanarb product group at the International Cardiovascular Intervention Conference held in Mexico on Feb. 23 (local time).
At this event, Mexican participants paid much attention to the clinical results of the Kanarb effect on proteinuria added as an indication other than hypertension, the effect of Kanarb in reducing the risk of stroke recurrence and cardiovascular disease, and the effect of Kanarb in elderly hypertensive patients.
In addition, Boryung will ramp up the Kanarb product group’s market share in Mexico by expanding its product lineup and strengthening marketing. To this end, Boryung is strengthening cooperation with its local partner, Stendhal. The two companies signed an MOU on Feb. 22 to launch Ducarb Plus in Mexico within this year.
In Mexico, Kanarb hit the shelves in 2014, Kanarb Plus in 2016, Ducarb in 2019, and Tuvero in 2020. They have come into spotlight as an effective treatment option for doctors and patients. At the moment, the Kanarb product group’s cumulative sales reached about US$150 million in Mexico.